Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Evaluating M1774, an ATR Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive and HER2-negative, Advanced Breast Cancers, Resistant to CDK4/6 Inhibitor Plus Aromatase Inhibitor-based Endocrine Treatment

NCT05986071 is registered in ClinicalTrials.gov with Institut Paoli-Calmettes as lead sponsor.

NCT NCT05986071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05986071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Evaluating M1774, an ATR Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive and HER2-negative, Advanced Breast Cancers, Resistant to CDK4/6 Inhibitor Plus Aromatase Inhibitor-based Endocrine Treatment
Lead sponsor
Institut Paoli-Calmettes
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
May 1, 2024
Completion date
October 15, 2027
Enrollment
57 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer